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Abstract
Human induced pluripotent stem cells (iPSCs) are a valuable tool for studying the cardiac developmental process
in vitro, and cardiomyocytes derived from iPSCs are a putative cell source for personalized medicine. Changes in
mitochondrial morphology have been shown to occur during cellular reprogramming and pluripotent stem cell
differentiation. However, the relationships between mitochondrial dynamics and cardiac mesoderm commitment of
iPSCs remain unclear. Here we demonstrate that changes in mitochondrial morphology from a small granular
fragmented phenotype in pluripotent stem cells to a ﬁlamentous reticular elongated network in differentiated
cardiomyocytes are required for cardiac mesodermal differentiation. Genetic and pharmacological inhibition of the
mitochondrial ﬁssion protein, Drp1, by either small interfering RNA or Mdivi-1, respectively, increased cardiac
mesoderm gene expression in iPSCs. Treatment of iPSCs with Mdivi-1 during embryoid body formation signiﬁcantly
increased the percentage of beating embryoid bodies and expression of cardiac-speciﬁc genes. Furthermore, Drp1
gene silencing was accompanied by increased mitochondrial respiration and decreased aerobic glycolysis. Our
ﬁndings demonstrate that shifting the balance of mitochondrial morphology toward fusion by inhibition of Drp1
promoted cardiac differentiation of human iPSCs with a metabolic shift from glycolysis towards oxidative
phosphorylation. These ﬁndings suggest that Drp1 may represent a new molecular target for future development of
strategies to promote the differentiation of human iPSCs into cardiac lineages for patient-speciﬁc cardiac regenerative
medicine.
Introduction
Induced pluripotent stem cells (iPSCs) represent a
major advance for potential autologous cell therapies.
Cardiomyocytes derived from iPSCs can be used for cell-
based therapy to treat heart disease, drug screening and
cardiac disease modelling. Several agents have been
shown to promote differentiation of pluripotent stem cells
toward cardiomyogenic lineages, mainly through manip-
ulation of the transforming growth factor-β (TGF-β),
Nodal, Wnt, Notch and ﬁbroblast growth factor signalling
pathways1,2. However, the biological mechanisms
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governing commitment of iPSCs to cardiomyocyte lineage
are still poorly understood. Thus, further understanding
the cellular and molecular events guiding the cardiac
differentiation of human iPSCs are crucial for developing
more robust and reproducible cardiac differentiation
protocols, as well as improving our understanding of key
regulatory machineries of human heart development.
Mitochondria are dynamic organelles which con-
tinuously alter their morphology by undergoing fusion
and ﬁssion processes to generate elongated and frag-
mented mitochondria, respectively. These two opposing
processes are essential to maintain mitochondrial integ-
rity and homoeostasis, and are regulated by a group of
evolutionarily conserved mitochondrial fusion and ﬁssion
proteins3. Studies have reported that mice lacking the
mitochondrial ﬁssion (Drp1 and Mff) or fusion (Mfn1,
Mfn2 and Opa1) proteins all exhibit developmental car-
diac defects and increased susceptibility to cardiac
injury4,5, underscoring the importance of mitochondrial
dynamics in cardiac development and disease. Studies
using iPSCs have reported a critical role of mitochondrial
fusion and ﬁssion proteins in pluripotency induction6,7. In
mouse embryonic ﬁbroblasts, Mfn1/2 ablation facilitated
somatic cell reprogramming to pluripotent stem cells6,
whereas pharmacological inhibition of mitochondrial ﬁs-
sion protein Drp1 limited cell fate conversion toward
pluripotency7. Furthermore, mitochondrial fusion has
been demonstrated to be essential for cardiac differ-
entiation of murine embryonic stem cells, with embryonic
stem cells deﬁcient in mitochondrial fusion proteins Mfn2
and Opa1 having impaired ability to differentiate into
cardiomyocytes8, indicating that mitochondrial morphol-
ogy is an important regulator of cell fate.
In light of these ﬁndings, we hypothesized that inhi-
biting the dynamin-related GTPase Drp1, a key regulator
of mitochondrial ﬁssion, can promote cardiac differ-
entiation of iPSCs. To test this hypothesis, we employed
siRNA-mediated gene silencing approach to knockdown
Drp1 expression in human iPSCs. For timely manipula-
tion of mitochondrial morphology, we employed Mdivi-1,
a cell-permeable quinazolinone derivative small molecule,
to reversibly inhibit Drp1, in both two-dimensional and
three-dimensional cultures of iPSCs. For mechanistic
insights, we studied the kinase proﬁle of Mdivi-1 and
changes in mitochondrial bioenergetics following inhibi-
tion of Drp1.
Results
Changes in mitochondrial morphology during cardiac
differentiation
To investigate the regulation of mitochondrial mor-
phology during cardiac differentiation of human iPSCs,
the morphology of mitochondria and expression of genes
related to mitochondrial morphology were compared
between undifferentiated iPSCs and derived cardiomyo-
cytes. In the pluripotent state, iPSCs (iPS-Foreskin-2 cell
line) have fragmented and punctate mitochondria with
perinuclear localization. As iPSCs differentiated into
cardiomyocytes, the granular mitochondria became more
tubular and formed net-like reticular networks through-
out the cytoplasm (Fig. 1a, b), consistent with previous
ﬁndings in embryonic stem cells showing substantial
structural changes and distribution of mitochondria dur-
ing differentiation8. These changes in morphology were
accompanied by a signiﬁcantly lower mRNA expression of
the mitochondrial ﬁssion protein, Drp1 (DNM1L), and a
higher mRNA expression of MFN2 (a mitochondrial
fusion protein) in the derived cardiomyocytes (Fig. 1c).
The lower mRNA expression of Drp1 in cardiomyocytes
compared to undifferentiated iPSCs was also observed in
another iPSC line, CERA007c6. However, in CERA007c6
iPSCs, the mRNA expression of MFN2 was similar
between undifferentiated iPSCs and the derived cardio-
myocytes while the mRNA expression of MFN1 was sig-
niﬁcantly lower in the derived cardiomyocytes
(Supplemental Figure S1A). Successful induction of car-
diomyocytes from iPSCs was conﬁrmed by spontaneous
contraction and a signiﬁcant up-regulation in expression
level of cardiac troponin T, TNNT2 (Fig. 1d; Supple-
mental Figure S1B). These observations prompted us to
investigate the role of the mitochondrial ﬁssion protein
Drp1 in regulating cardiac mesoderm differentiation of
iPSCs.
Drp1 gene silencing commits iPSCs toward cardiac
mesoderm lineage
To evaluate the functional role of Drp1 in iPSCs,
undifferentiated iPSCs cultured in the TeSR-E8 plur-
ipotency-maintaining medium were transiently trans-
fected with Drp1 siRNA, which effectively reduced Drp1
protein and gene expression without affecting the
expression of FIS1, MFF, MFN1, MFN2 and OPA1
(Fig. 2a, b, Supplemental Figure S2). Knockdown of Drp1
in iPSCs (iPS-Foreskin-2 cell line) for 2 days signiﬁcantly
increased the proportion of OCT3/4-positive cells with
elongated mitochondria (Fig. 2c). This shift in mito-
chondrial morphology was accompanied by signiﬁcant
up-regulation in expression of early mesodermal gene
brachyury (T) and cardiac progenitor gene TBX5 (Fig. 2d),
while the mRNA expression of ectodermal (PAX6 and
TUBB3) and endodermal (AFP and CDH1) markers was
not signiﬁcantly affected by Drp1 knockdown (Supple-
mentary Figure S3). The mRNA expression of plur-
ipotency factor SOX2, but not NANOG, was signiﬁcantly
down-regulated in Drp1-knockdown iPSCs (Fig. 2e).
Analysis of mRNA expression levels of cell cycle markers
showed reduced expression of MIK67 but not AURKB,
indicating reduced cell proliferation without affecting
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cytokinesis in Drp1-knockdown iPSCs (Fig. 2f). Similar
results were obtained with CERA007c6 iPSC line,
although increased expression of cardiac transcription
factor NKX2.5 and reduced expression of cell cycle reg-
ulatory gene AURKB were also detected in Drp1-
knockdown CERA007c6 iPSCs (Supplemental Fig-
ure S2). The effect of Drp1 inhibition on iPSCs was fur-
ther conﬁrmed with Mdivi-1, a small molecule that
prevents the GTPase activity of Drp1 and its poly-
merization at the outer mitochondrial membrane9. Two
days treatment with Mdivi-1 signiﬁcantly increased the
proportion of OCT3/4-positive cells with tubular mito-
chondria and expression ofMFN2, while the expression of
other mitochondrial ﬁssion (DNM1L, FIS1 and MFF) and
fusion (MFN1 and OPA1) genes were not affected (Sup-
plemental Figure S4). Mdivi-1-treated cells also have
higher expression of early mesodermal gene brachyury (T)
and lower expression of cell cycle marker MIK67 com-
pared to the vehicle control group (Supplemental Fig-
ure S4). These data indicate that both genetic knockdown
and pharmacological inhibition of Drp1 initiates cardiac
mesoderm differentiation from human iPSCs.
Pharmacological inhibition of Drp1 with Mdivi-1 promotes
cardiac differentiation
To further evaluate the role of Drp1 in cardiac differ-
entiation of iPSCs, an EB-based spontaneous differentia-
tion method was employed to rule out the potential
confounding inﬂuence of cardiogenic factors needed for
directed cardiac differentiation of iPSC in monolayer
format. Limited by the poor transfection efﬁciency of
three-dimensional structure of EBs with siRNA, Mdivi-1
was used to inhibit Drp1 during EB formation (Fig. 3a).
Treatment of iPSCs (iPS-Foreskin-2 cell line) with 5 µM
of Mdivi-1 during EB formation resulted in a 3- to 4-folds
increase in the percentage of beating EBs at day 10 post-
plating (Fig. 3b). Treatment duration did not signiﬁcantly
affect the pro-cardiogenic effect of Mdivi-1 since treat-
ment during the ﬁrst 3 days or the last 3 days of EB
formation resulted in a similar increased in the percentage
Fig. 1 Mitochondrial morphology of human iPSCs and derived cardiomyocytes in iPS-Foreskin-2 cell line. a Morphology of mitochondria in
undifferentiated iPSCs (Oct3/4-positive cells) and the derived cardiomyocytes (α-actinin-positive cells). Scale bars= 50 μm. b Percentage of cells with
different mitochondrial morphologies (n= 4 independent experiment). c, dmRNA expression of mitochondrial fusion and ﬁssion genes (c), as well as
cardiac-speciﬁc TNNT2 gene (d) in undifferentiated iPSCs (Undiff) and derived cardiomyocytes (CM) (n= 8 independent experiments). Data are
shown as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 by unpaired Student’s t-test
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of beating EBs as 6 days treatment with Mdivi-1 (Fig. 3b).
A similar increase in the percentage of beating EBs was
also observed in CERA007c6 iPSC line albeit at a lower
rate (percentage of beating EBs at day 10 post-plating=
2.8 ± 1.8% in control vs. 12.8 ± 3.7% in Mdivi-1 D0-6,
P < 0.05, n= 5). Despite the increase in the percentage of
beating EBs, the percentage of cardiac troponin T-positive
cardiomyocytes within each beating EB at day 10 post-
plating was similar among all treatment groups (Fig. 3c).
Quantitative PCR analysis conﬁrmed directed cardiac
differentiation of iPSCs (iPS-Foreskin-2 cell line) by
Mdivi-1 treatment (for 6 days during EB formation),
where expression of genes encoding cardiac transcription
factor GATA4, TBX5and NKX2.5 (Fig. 3d), as well as
cardiac structural and contractile proteins TNNT2,
TNNI3, MYH6 and MYL7 (Fig. 3e) were signiﬁcantly up-
regulated in 6-day-old EBs. In parallel, transcripts for
mitochondrial ﬁssion proteins DNM1L and MFF, and
mitochondrial fusion protein MFN1 were signiﬁcantly
up-regulated in Mdivi-1-treated EBs compared to control
group (Fig. 3f).
Beating EBs from both control and Mdivi-1-treated
groups were capable of cycling calcium as determined by a
ﬂuorescent calcium indicator Fluo-4 AM. Extracellular
ﬁeld potentials measured by MEA showed an average
contraction rate of 77 ± 3 bpm in the control group and
79 ± 4 bpm in the Mdivi-1-treated group. Isoproterenol
(Fig. 3g) and carbamylcholine (Fig. 3h) produced a
concentration-dependent positive and negative chrono-
tropic responses, respectively, in both control and Mdivi-
1-treated beating EBs. These results suggest that Mdivi-1
treatment did not affect the electrophysiological proper-
ties of cardiomyocytes derived from iPSCs.
Speciﬁcity of Mdivi-1 towards Drp1
Mdivi-1 is a quinazolinone derivative that inhibits Drp1
assembly on the outer mitochondrial membrane by pre-
venting the polymerization of higher order structures9.
Fig. 2 Drp1 knockdown in human iPSCs induces cardiac mesoderm differentiation. a Western blotting analysis of Drp1 expression (n= 4
independent experiments) and b RT-qPCR analysis of mitochondrial fusion and ﬁssion gene expression (n= 7–11 independent experiments) in iPS-
Foreskin-2 cells treated with scrambled (control) or DRP1 siRNA. c Morphology of mitochondria and percentage of Oct3/4-positive cells with different
mitochondrial morphologies (n= 4 independent experiment). d–f mRNA expression of cardiac mesoderm transcription factors (d), pluripotency
genes (e) and cell proliferation genes (f) in iPS-Foreskin-2 cells treated with scrambled (control) or Drp1 siRNA (n= 8–11 independent experiments).
Data are shown as mean ± SEM. *P < 0.05, ***P < 0.001, ****P < 0.0001 by unpaired Student’s t-test
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Fig. 3 Mdivi-1 promotes cardiac differentiation of human iPSCs. a Schematic of the embryoid body-based cardiac differentiation protocol. b
Effect of Mdivi-1 on the percentage of beating EBs (n= 7–8 independent experiments). c Percentage of cardiac troponin T-positive cells in each
beating EB at day 10 post-plating (n= 8–10 independent experiments). d–f mRNA expression of cardiac mesoderm transcription factors (d), cardiac
muscle proteins (e) and mitochondrial fusion and ﬁssion protein (f) (n= 4 independent experiments) in iPS-Foreskin-2 cells treated with DMSO
(control) or 5 µM Mdivi-1 for 6 days during embryoid body formation. Changes in the beating rate of cardiomyocytes derived from control or Mdivi-1
groups treated with isoproterenol hydrochloride (isoprenaline, 1–1000 nM) (g) or carbamylcholine (carbachol, 1–1000 nM) (h) (n= 10 independent
experiments). Data are expressed as mean ± SEM. *P < 0.05 and ***P < 0.001 vs. control (a–f) or baseline (g, h) by one-way ANOVA with the Bonferroni
post hoc test
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However, a recent study by Bordt et al.10 has shown that
Mdivi-1 can inhibit respiratory complex I and this has
challenged the speciﬁcity of Mdivi-1 as a selective inhi-
bitor of Drp1. Using human recombinant Drp1 proteins,
we showed that Mdivi-1 inhibits GTPase activity of Drp1
in a dose-dependent manner (Fig. 4a). To evaluate whe-
ther Mdivi-1 might also inhibit GTPase activity of Drp1
indirectly through interaction of other protein kinases, a
high-throughput ATP-independent kinase assay was
performed. Kinase screening against a panel of 468
human kinases with KINOMEscan assay showed a
potential weak thermodynamic interaction between
Mdivi-1 and protein kinase CK2α’ (CSNK2A2) (Fig. 4b,
Supplementary Table S1) with a percent of control of
35%. To further assess this binding afﬁnity of Mdivi-1
toward CK2 protein kinase, a cell-free in vitro CK2 kinase
activity assay was performed using tetrabromocinnamic
acid as a positive control. While tetrabromocinnamic acid
exhibited a dose-dependent inhibition of CK2α and CK2α
′ activities, Mdivi-1 did not signiﬁcantly modulate CK2α
and CK2α′ activities (Fig. 4c). In iPSCs, treatment with
Mdivi-1 also did not affect the transcripts for CK2α
(CSNK2A1) and CK2α′ (CSNK2A2) (Fig. 4d).
Despite in vitro insensitivity of CK2α activity to Mdivi-
1, CK2α mRNA levels were signiﬁcantly lower in differ-
entiated cardiomyocytes compared to undifferentiated
iPSCs (Supplemental Figure S5A). We considered that the
pro-cardiogenic effect of Drp1 inhibition might involve
protein kinase CK2. Knockdown of Drp1 in iPSCs did not
change the mRNA and protein expression levels of CK2α
and CK2α′ (Supplemental Figure S5B-C). Vice versa,
knockdown of CK2α and CK2α′ did not signiﬁcantly
affect the mRNA expression of mitochondrial fusion and
ﬁssion proteins or cardiac mesoderm-related transcrip-
tion factors (Supplemental Figure S5D-F). Altogether,
these data demonstrate that CK2 kinase is not involved in
the pro-cardiogenic effect of Drp1 inhibition.
Drp1 gene silencing induces metabolic switch
Pluripotent stem cell metabolism is predominantly
glycolytic which is in contrast to oxidative-based meta-
bolism of cardiomyocytes11. To determine whether a
metabolic switch from glycolysis to oxidative phosphor-
ylation may underlie the pro-cardiogenic effect of Drp1
inhibition, the metabolic phenotypes of iPSCs were ana-
lysed using a Seahorse extracellular ﬂux analyser with
oxygen consumption rates (OCRs) and extracellular
acidiﬁcation rates (ECARs) as readouts for oxidative
phosphorylation and glycolysis, respectively. Human
iPSCs (iPS-Foreskin-2 cell line) showed oligomycin-
sensitive oxygen consumption, and knockdown of Drp1
with siRNA signiﬁcantly increased basal respiration (basal
OCRs), maximal respiration, proton leak and ATP pro-
duction, indicating increased oxidative phosphorylation
(Fig. 5a). On the contrary, Drp1 gene silencing sig-
niﬁcantly reduced glycolysis, glycolytic capacity and gly-
colytic reserve in iPSCs (Fig. 5b). Interestingly, these
changes in metabolic proﬁles were not recapitulated with
Mdivi-1 treatment. Treatment with Mdivi-1 at a regimen
(5 µM for 2 days) that promoted mitochondrial tubulation
and cardiac mesodermal gene expression (Supplemental
Figure S4) signiﬁcantly reduced basal respiration, max-
imal respiration and ATP production in iPSCs, without
signiﬁcantly affecting glycolysis as determined by the
ECAR (Supplemental Figure S6B). Neither Drp1 gene
silencing nor Mdivi-1 treatment signiﬁcantly affected the
mRNA expression of peroxisome proliferator-activated
receptor gamma coactivator 1α (PPARGC1A) and mito-
chondrial transcriptional factor-A (TFAM), two major
regulators of mitochondrial biogenesis (Supplemental
Figure S7). Overall these results suggest that Drp1 gene
silencing induces a bioenergetics switch from glycolysis to
oxidative metabolism.
Discussion
Mitochondria are metabolic organelles that play an
important role in various physiological functions includ-
ing cell metabolism, proliferation, apoptosis and stem cell
differentiation. The shape of mitochondria changes dur-
ing cell fate conversion, from somatic cells with fused
mitochondria to pluripotent stem cells with fragmented
mitochondria and again in reverse as they differentiate
into somatic cells6,7,12. This phenomenon highlights the
importance of mitochondrial morphology in cell repro-
graming and stem cell differentiation. In this study, we
uncovered a regulatory role of mitochondrial ﬁssion
protein Drp1 in early cardiac mesodermal differentiation
of human pluripotent stem cells, where inhibition of Drp1
promotes cardiac differentiation of iPSCs and this process
was accompanied by a shift in mitochondrial dynamic
equilibrium toward fusion and changes in mitochondrial
bioenergetics from glycolysis to oxidative phosphorylation
for energy production.
Drp1-mediated mitochondrial ﬁssion is implicated in
maintenance of cell pluripotency and pluripotent cell
reprogramming13–15. Inhibition of mitochondrial ﬁssion
with either small interference RNA targeting Drp1,
overexpression of a dominant-negative Drp1 or treatment
with the Drp1 inhibitor Mdivi-1 diminishes the repro-
gramming efﬁciency of somatic cells into pluripotent stem
cells7,14. As embryonic stem cells exit pluripotency and
differentiate, mitochondria change their fragmented
morphology and perinuclear localization to an elongated
morphology that extends throughout the cytoplasm12,16.
Similar morphological changes that we also observed in
human iPSCs as they differentiate into cardiomyocytes. A
previous study has implicated the importance of mito-
chondrial fusion proteins for cardiac development of
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Fig. 4 Effect of Mdivi-1 on Drp1 GTPase activity and other protein kinases. a GTPase activity of human recombinant Drp1 protein in the
presence and absence of Mdivi-1. b Kinase interaction map of Mdivi-1 (10 µM) with 468 human protein kinases. The size of circle represents the
relative binding score for each kinase. Mdivi-1 has one potential candidate kinase target, protein kinase CK2α′, with a binding score of 35% relative to
the DMSO control. c Activities of protein kinase CK2α and CK2α′ in the presence or absence of Mdivi-1 or tetrabromocinnamic acid (TBCA) (n= 3). d
mRNA expression of protein kinase CK2α and CK2α′ in iPS-Foreskin-2 cells treated with DMSO (control) or 5 µM Mdivi-1 (n= 9 independent
experiments). Data are expressed as mean ± SEM. **P < 0.01, ***P < 0.001, ****P < 0.0001 by one-way ANOVA with the Bonferroni post hoc test
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murine cardiomyocytes by demonstrating that knock-
down of pro-fusion proteins, Mfn2 and Opa1, impairs the
ability of murine embryonic stem cells to undergo cardiac
differentiation8. While they reported increase in Mfn2 and
Opa1 expression as embryonic stem cells differentiate
into cardiomyocytes, we detected a reduced expression of
Drp1 in cardiomyocytes differentiated from human iPSCs.
We further demonstrated that shifting the mitochondrial
morphology toward fusion by silencing the expression of
Drp1, or by inhibiting the activity of Drp1 with Mdivi-1,
promotes cardiac mesodermal differentiation of human
iPSCs. In addition to pluripotent stem cells, Drp1-
dependent mitochondrial ﬁssion has also been impli-
cated in maintaining the stemness of human nasophar-
yngeal carcinoma17, mouse skin mesenchymal stem cells18
and myogenic precursor cells19. These ﬁndings highlight
the important role of mitochondrial dynamic in stem cell
fate determination.
Metabolism is closely linked to cell fate20. Pluripotent
stem cells have a high glycolytic ﬂux and a relatively low
mitochondrial respiration even when cultured in an
oxygen-rich environment21–23. Compared to oxidative
metabolism, glycolysis generates more energy and
produces less reactive oxygen species and thus less DNA
damage, which are essential for maintaining genomic
integrity and healthy cell proliferation of pluripotent stem
cells24. During the process of reprograming to iPSCs,
somatic cells undergo a transition from mitochondrial
respiration to aerobic glycolysis for more efﬁcient gen-
eration of ATP and nucleotides to cope with the highly
proliferative state of pluripotent stem cells25,26. Although
impairment of Complex I mitochondrial respiration does
not signiﬁcantly impact on the efﬁciency of iPSC repro-
graming27, stimulation of glycolytic ﬂux by glucose sup-
plementation increases the efﬁciency of induced
pluripotent reprogramming25. On the other hand, mito-
chondrial metabolism switches from aerobic glycolysis to
favour oxidative phosphorylation-based metabolism when
pluripotent stem cells exit the pluripotent state and dif-
ferentiate28,29. Furthermore, this metabolic shift has been
shown to occur prior to the loss of pluripotency24, and
inhibition of glycolysis with glycolytic inhibitors upstream
of acetate such as 2-deoxy-D-glucose and 3-
bromopyruvate results in spontaneous differentiation of
pluripotent stem cells29. Interestingly, a metabolic switch
away from glycolysis during pluripotent stem cell
Fig. 5 Drp1 knockdown in human iPSCs induces metabolic switch from glycolysis to oxidative phosphorylation. a Oxygen consumption rate
(OCR) and b extracellular acidiﬁcation rate (ECAR) of iPS-Foreskin-2 cells treated with scrambled (control) or Drp1 siRNA (n= 4 independent
experiments). Data are shown as mean ± SEM. *P < 0.05, **P < 0.01, ****P < 0.0001 by unpaired Student’s t-test
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differentiation has been shown to be speciﬁc for meso-
derm and endoderm lineages while early ectoderm dif-
ferentiation requires maintenance of high glycolytic ﬂux
and is regulated by MYC transcription factors30. In
human iPSCs, we showed a shift in metabolism from
glycolysis toward oxidative phosphorylation when Drp1 is
knocked down. This metabolic change was associated
with increased expression of cardiac mesodermal markers
and reduced expression of pluripotency factor Sox2,
demonstrating the close relationship between mitochon-
drial morphology, energy metabolism and pluripotency.
This is in agreement with previous studies that reported
an increase in mitochondrial oxidative respiration and
mitochondrial elongation when stem cells lose their
pluripotency16, while induction of mitochondrial ﬁssion,
either via activation of mitochondrial ﬁssion protein Drp1
or by depletion of mitochondrial fusion protein Mfn1/2,
induces metabolic shift in dependency of aerobic glyco-
lysis to oxidative phosphorylation and promotes repro-
graming of somatic cells into iPSCs6,13.
Mdivi-1 is a quinazolinone derivative and a selective
cell-permeable allosteric inhibitor of Drp1. Mechan-
istically, Mdivi-1 inhibits GTPase activity of Drp1 and
prevents their assembly on the outer mitochondrial
membrane by preventing the polymerization of higher
order structures9,31. Although Mdivi-1 has been shown to
inhibit GTPase activity of Dnm1, the yeast homologue of
the mammalian Drp19, the GTPase inhibitory effect of
Mdivi-1 on recombinant human Drp1 has been con-
troversial9,10. Using a different source of recombinant
human Drp1 (isoform 2) that has 76% of amino acid
sequence matching endogenous Drp1, we observed a
signiﬁcant reduction of GTPase activity of the recombi-
nant human Drp1 when pre-incubated with Mdivi-1 for at
least 30 min. This suggests the equilibrium binding
interaction between Mdivi-1 and Drp1 required time to
establish in a cell-free environment. Interestingly, while
Mdivi-1 recapitulated the effect of Drp1 silencing in
promoting mitochondrial fusion and cardiac mesodermal
differentiation in human iPSCs, Mdivi-1 did not induce a
metabolic shift as observed with Drp1 knockdown.
Instead, treatment with Mdivi-1 at 5 µM resulted in sig-
niﬁcant reduction in mitochondrial respiration. In fact, a
recent study in mouse embryonic ﬁbroblasts has
demonstrated that Mdivi-1 at a much higher concentra-
tion of 50 µM can reversibly inhibit mitochondrial com-
plex I-dependent oxygen consumption and reverse
electron transfer-mediated reactive oxygen species pro-
duction in a Drp1-independent manner10. However, the
inhibitory effect of Mdivi-1 on mitochondrial respiration
could be cell type speciﬁc given that Mdivi-1 does not
signiﬁcantly modify mitochondrial oxygen consumption
in human cardiac stem cells32. Although Mdivi-1 did not
signiﬁcantly interact with any of the 468 human protein
kinases in our kinase proﬁling assay, this ﬁnding does not
exclude the possibility that Mdivi-1 may interact with
other protein classes such as other hydrolase enzymes, G-
protein coupled receptors, ion channels, nuclear recep-
tors, transcription factors and plasma proteins, which
warrants further investigation.
In conclusion, manipulation of mitochondrial mor-
phology by inhibiting Drp1 promotes cardiac mesodermal
differentiation of human iPSCs, highlighting the reg-
ulatory importance of Drp1-mediated mitochondrial ﬁs-
sion in maintaining stem cell pluripotency and controlling
cell fate decisions.
Methods
Human iPSC culture and cardiac differentiation
The iPS-Foreskin-2 cell line was obtained from Prof J.
Thompson (University of Wisconsin, USA)33. CERA007c6
iPSC line was generated using skin ﬁbroblasts from a 36
years old healthy male by the episomal method as descri-
bed previously34. Human iPSCs were maintained on a
feeder layer of mitotically inactivated human foreskin
ﬁbroblasts (HFF:D551; ATCC, VA, USA) in Dulbecco's
modiﬁed Eagle's medium (DMEM)/F-12 GlutaMAX
medium supplemented with 20% knockout serum repla-
cement, 0.1mM 2-mercaptoethanol, 0.1mM nonessential
amino acids, 50 U/mL penicillin/streptomycin (all from
Thermo Fisher Scientiﬁc, VIC, Australia) and 20 ng/mL
recombinant human ﬁbroblast growth factor-2 (Merck
Millipore, CA, USA)35. For feeder-free culture, human
iPSCs were maintained and propagated on vitronectin-
coated plate in TeSR-E8 medium (Stem Cell Technologies,
VA, Canada) according to the manufacturer’s protocol.
Spontaneous differentiation of iPSCs was induced
through formation of embryoid bodies (EBs) as previously
described35. Brieﬂy, EBs were formed by mechanically
dissecting undifferentiated iPSC colonies maintained on a
feeder layer into approximately 0.2 mm2 pieces. Pieces
were transferred onto low attachment plates and cultured
in suspension in differentiation medium containing
DMEM/F-12 GlutaMAX medium supplemented with
20% foetal bovine serum (Sigma-Aldrich, MO, USA), 0.1
mM 2-mercaptoethanol, 0.1 mM nonessential amino
acids and 50 U/mL penicillin/streptomycin, where they
aggregated to form EBs over 6 days. During EB formation,
cells were treated with either 0.05% DMSO as vehicle
control or 5 µM Mdivi-1 (Enzo Life Sciences, NY, USA).
On day 6 (day 0 post-plating), EBs were transferred to
tissue culture plates pre-coated with 0.1% gelatin (Sigma-
Aldrich), and cultured in differentiation medium. The
percentage of contractile EBs was measured as the num-
ber of EBs that showed spontaneous contraction divided
by the total number of EBs plated.
For directed cardiac differentiation, iPSCs maintained
on feeder-free culture were dissociated into single cells
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with TrypLE (Thermo Fisher Scientiﬁc) and seeded onto
Matrigel (Corning, MA, USA) coated plate at a density of
1 × 105 cells/cm2 in TeSR-E8 medium supplemented with
10 µM Y-27632 (Tocris Bioscience, Bristol, UK). After
2 days when the cells were 100% conﬂuent, which is
referred to as day 0, medium was replaced with RPMI
1640 basal medium containing B-27 without insulin
supplement (Thermo Fisher Scientiﬁc), growth factor
reduced Matrigel (1:60 dilution) and 10 µM CHIR99021
(Cayman Chemical, MI, USA). After 24 h, cells were
treated with 5 ng/mL Activin A (Peprotech, NJ, USA) in
RPMI 1640 basal medium containing B-27 without insu-
lin supplement for 24 h. At day 2, the medium was
changed to RPMI 1640 basal medium containing B-27
without insulin supplement and 5 µM IWP2 (Tocris
Bioscience) for 72 h. From day 5 onward, cells were cul-
tured in RPMI 1640 basal medium containing B-27 sup-
plement (Thermo Fisher Scientiﬁc) and 200 µg/mL L-
ascorbic acid 2-phosphate sesquimagnesium salt hydrate
(Sigma-Aldrich).
Microelectrode array recordings
The electrophysiological properties of the cardiomyo-
cytes derived from iPS cells were evaluated using a
microelectrode array (MEA) recording system (Multi-
channel Systems, Reutlingen, Germany). Beating cell
clusters at day 10 post-plating were transferred onto MEA
plates coated with 0.1% gelatin and 10 µg/mL ﬁbronectin.
Responsiveness to pharmacological agents was deter-
mined 4–6 days later at 37 °C in Krebs-Ringer buffer
(composition in mM: 125 NaCl, 5 KCl, 1 Na2HPO4, 1
MgSO4, 20 HEPES, 5.5 glucose, 2 CaCl2; pH 7.4). The
responsiveness of cells to isoproterenol hydrochloride
(1–1000 nM, Sigma-Aldrich) and carbamylcholine
(1–1000 nM, Sigma-Aldrich) was tested. Each cell cluster
was treated with all drugs in random order and cells were
allowed to recover to their baseline contraction in fresh
Krebs-Ringer buffer in between drug treatments. Extra-
cellular ﬁeld potentials were recorded at baseline and 2
min after addition of drugs. Data were analysed ofﬂine
with MC Rack version 4.3.5 software for beating rate, RR
interval and extracellular ﬁeld potential duration (FPD) as
previously described35,36. FPD measurements were nor-
malized (corrected FPD, cFPD) with the Bazzet correction
formula: cFPD= FPD/√(RR interval).
Small interfering RNA knockdown assay
iPSCs maintained on feeder-free culture were trypsi-
nized and seeded on Matrigel-coated surface at a density
of 5 × 104 cells/cm2 in TeSR-E8 medium supplemented
with 10 µM Y-27632. After overnight incubation, cells
were transfected with corresponding siRNA using the
Lipofectamine RNAiMAX transfection agent (Thermo
Fisher Scientiﬁc) for 2 days in TeSR-E8 medium. For
knockdown experiments, Drp1 (DNM1L) was silenced
with 50 pmol of siRNA duplex (sc-43732; Santa Cruz
Biotechnology, TX, USA). CK2α (CSNK2A1) and CK2α′
(CSNK2A2) were silenced with 50 pmol of ON-
TARGETplus SMARTpool siRNA system (Thermo
Fisher Scientiﬁc) which contains a pool of four different
siRNAs.
Immunocytochemistry
Cells were ﬁxed in 4% paraformaldehyde and permea-
bilized with 0.2% triton X-100. After blocking with serum-
free blocking solution (Thermo Fisher Scientiﬁc) for 10
min, cells were incubated with primary antibodies against
Oct3/4 (20 µg/mL, mouse monoclonal IgG; Santa Cruz
Biotechnology, TX, USA), cardiac troponin T (cTnT, 2
µg/mL, mouse monoclonal IgG; Abcam, MA, USA), α-
actinin (25 µg/mL, mouse monoclonal IgG, A7811;
Sigma-Aldrich), or Hsp60 (1.58 µg/mL, rabbit polyclonal
IgG, Abcam) at 4 °C overnight followed by Alexa Fluor
488 goat anti-mouse IgG, Alexa Fluor 488 goat anti-rabbit
IgG or Alexa Fluor 594 goat anti-mouse IgG (10 µg/mL;
Thermo Fisher Scientiﬁc) for 60min at room tempera-
ture. Cells were counterstained with 1 µg/mL DAPI
(Thermo Fisher Scientiﬁc) for nuclear staining and
mounted with ﬂuorescence mounting agent (DAKO,
Victoria, Australia). Images were acquired with a BX-61
Olympus ﬂuorescence microscope (Tokyo, Japan).
For quantitative assessment of cardiomyocytes differ-
entiation, spontaneously beating colonies at 10 days post-
plating were trypsinized into single-cell suspension with
0.25% trypsin-EDTA and spun onto coated glass slides (4
min at 900 rpm; Shandon Cytospin 4; Thermo Fisher
Scientiﬁc) and immunostained with cardiac troponin T
followed by Alexa Fluor 488 goat anti-mouse IgG. Cells
were counterstained with DAPI and mounted with
ﬂuorescence mounting agent. Images were taken with a
BX-61 Olympus ﬂuorescence microscope and at least 500
cells were counted.
Real-time quantitative PCR (RT-qPCR)
RNA was extracted from cells using TriReagent
(Thermo Fisher Scientiﬁc) followed by RNA precipitation
with chloroform and isopropanol (Sigma-Aldrich). cDNA
was synthesized using the high-capacity cDNA reverse
transcription kit (Applied Biosystems, CA, USA). qPCR
was carried out using TaqMan Universal master mix, the
7900HT Fast Real-Time PCR system and TaqMan gene
expression assays (Applied Biosystems) for GAPDH
(Hs03929097_g1), T (Hs00610080_m1), MESP1
(Hs00251489_m1), TBX5 (Hs00361155_m1), GATA4
(Hs00171403_m1), NKX2.5 (Hs00231763_m1), MEF2C
(Hs00231149_m1), ACTC1 (Hs01109515_m1), TNNT2
(Hs01109515_m1), TNNI3 (Hs00165957_m1), MYH6
(Hs01101425_m1), MYH7 (Hs00165276_m1), MYL2
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(Hs00166405_m1), MYL7 (Hs01085598_g1), AURKB
(Hs00945855_g1), MIK67 (Hs01032443_m1), NANOG
(Hs04260366_g1), SOX2 (Hs01053049_s1), DNM1L
(Hs00247147_m1), FIS1 (Hs00211420_m1), MFF
(Hs00697394_g1), MFN1 (Hs00966851_m1), MFN2
(Hs00208382_m1), OPA1 (Hs01047013_m1),CSNK2A1
(Hs00751002_s1), CSNK2A2 (Hs00176505_m1), TFAM
(Hs00273372_s1), PPARGC1A (Hs00173304_m1), PAX6
(Hs01088112_m1), TUBB3 (Hs00801390_s1), AFP
(Hs01040598_m1) and CDH1 (Hs01023894_m1). All
readings were performed in duplicate. The relative
quantitation was calculated by applying the comparative
CT method (2−ΔΔCt) whereby the mRNA expression
levels were normalized against the level of the house-
keeping human gene GAPDH (ΔCt) with the level of
candidate genes in control samples used as the reference
(ΔΔCt).
Western blotting
Proteins from iPSCs were extracted with RIPA lysis
buffer (Sigma-Aldrich) supplemented with protease inhi-
bitor cocktail (Sigma-Aldrich). Proteins were denatured in
NuPAGE LDS sample buffer (Thermo Fisher Scientiﬁc)
and separated by SDS-PAGE using NuPAGE 12% Bis-Tris
protein gels (Thermo Fisher Scientiﬁc) in NuPAGE MES
SDS running buffer (Thermo Fisher Scientiﬁc). Proteins
were then transferred onto a polyvinylidene diﬂuride
membrane (Amersham Hybond; GE Healthcare Life Sci-
ences, NSW, Australia) and blocked with Odyssey
blocking buffer (LI-COR Biosciences, NE, USA) for 30
min at room temperature. Following successive washes in
phosphate-buffered saline (PBS) containing 0.1% Tween-
20 (PBS-T), membranes were incubated with the follow-
ing primary antibodies diluted in PBS-T: mouse mono-
clonal Drp1 (1 µg/mL; Abcam), mouse monoclonal CKII-
alpha (4 µg/mL; Abcam), rabbit polyclonal CKII-alpha
prime (2 µg/mL; Abcam) or mouse monoclonal β-actin
(1:1000 dilution; LI-COR Biosciences) at 4 °C overnight.
After three washes in PBS containing 0.1% Tween-20,
membranes were incubated with appropriate ﬂuores-
cently labelled secondary antibodies, either Alexa ﬂuor-
680 donkey anti-rabbit (0.1 µg/mL; Thermo Fisher Sci-
entiﬁc) or IRDye® 800CW goat anti-mouse (0.05 µg/mL;
LI-COR Biosciences) for 1 h at room temperature. The
membranes were scanned with Odyssey infrared imaging
system (LI-COR Biosciences) and protein band intensity
was determined by computerized densitometry using NIH
Image J software and expressed as arbitrary units after
normalized with β-actin.
KINOMEscan
The active site-directed competition binding assays
were performed using the KINOMEscan kinase proﬁling
platform (DiscoverX, CA, USA). KINOMEscan assay do
not require ATP and thus report true thermodynamic
interaction afﬁnities37. The assays measured the interac-
tions of Mdivi-1 (10 µM in 0.1% DMSO) with 468 kinases
covering more than 80% of the human kinome and
disease-relevant mutant variants. Kinase dendrogram was
generated using TREEspot software (http://www.
kinomescan.com). The readout from KINOMEscan
assay is ‘percent of control’, where the control is 0.1%
DMSO and 100% indicates no inhibition of the kinase by
Mdivi-1 at 10 µM.
Recombinant his6-Drp1 production and puriﬁcation
For bacterial expression of recombinant human Drp1
(N-term his6) protein, cDNA for human Drp1 (Isoform 2,
Uniprot ID: O00429-3) was cloned into pQE-30 vector
and transformed in Rosetta (DE3) competent cells
(Novagen, Merck Millipore). Transformed cells were
propagated in a shaker incubator in 2 L Luria-Bertani
broth, in the presence of 100 µg/mL ampicillin at 37 °C,
120 rpm to A600= 2–2.5. Protein expression was induced
by addition of 0.5 mM IPTG, after which cultures were
incubated at 16 °C for 20–22 h. Cells were harvested by
centrifugation at 3500 rpm, 20min and the pellet re-
suspended in lysis buffer containing 50mM Tris.HCl (pH
7.3), 0.5M NaCl, 50 mM imidazole, 5% glycerol, 2 mM β-
mercaptoethanol, 0.1 mM LEUPEP, 0.1 mM AEBSF and 1
mM benzaminidium chloride. Cell were lysed using a pre-
cooled EmulsiFlex-C5 homogenizer (Avestin, Ottawa,
Canada). Cell lysates were clariﬁed by centrifugation at
20,000 rpm for 30min and loaded onto a 5 mL Nickel
Chelating Sepharose Fast Flow column (GE Healthcare,
Buckinghamshire, UK). The column was washed with 20
column volumes of lysis buffer without addition of pro-
tease inhibitors. Drp1 protein was eluted with 50mM
Tris.HCl (pH 7.6), 150 mM NaCl, 400 mM imidazole, 10%
glycerol and 2mM β-mercaptoethanol and exchanged
into storage buffer (50 mM Tris.HCl (pH 7.6), 150mM
NaCl, 10% glycerol, 2 mM TCEP) using a PD-10 desalting
column (GE Healthcare) and aliquots stored at −80 °C.
Mammalian cell expression of HA-tagged CK2α and CK2α′
CK2α (Uniprot P68400, C-terminal HA-tagged,
Addgene plasmids #27086) and CK2α′ (Uniprot P19784,
N-terminal HA-tagged, Addgene plasmids #27087) pro-
teins (gifts from David Litchﬁeld) were expressed in COS7
cells which were cultured in DMEM medium supple-
mented with 10% foetal bovine serum and incubated at
5% CO2 at 37 °C. Cells were transfected with 2 μg plasmid
DNA per 10 cm culture dish, using FuGENE HD (Pro-
mega, WI, USA) according to the manufacturer’s
instruction. Cells were harvested 48 h post-transfection
and lysed in ice cold 50 mM Tris-HCl (pH 7.4), 50 mM
NaCl, 10% glycerol, 1 mM EDTA, 1 mM EGTA, 5 mM
sodium pyrophosphate, 50 mMNaF, 1% Triton X-100 and
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cOmplete protease inhibitor cocktail (Roche, Basel,
Switzerland). Lysates were clariﬁed by centrifugation
(14,000 rpm, 10min, 4 °C). Supernatants containing
expressed CK2 proteins were used for subsequent
immunoprecipitation experiments or stored at −80 °C for
further use.
CK2 kinase activity assay
CK2 kinase activity was assayed using radiolabelled 32P-
ATP and synthetic peptide substrate CKtide
(RRRDDDSDDD-NH2). CK2α and CK2α′ proteins from
prepared lysates was immobilized on anti-HA afﬁnity gel
(Sigma-Aldrich) and washed four times with wash buffer
(50 mM HEPES (pH 7.4), 150mM NaCl, 10% glycerol, 1
mM DTT and 0.1% Tween-20) prior to the kinase reac-
tion. Activity assay was conducted in the presence of 200
µM CKtide peptide, 5 mM MgCl2, 200 µM [γ-
32P] ATP
for 10 min at 30 °C, in the presence or absence of 0.05–50
µM Mdivi-1 or tetrabromocinnamic acid (Calbiochem,
MA, USA). Phosphotransferase activity was quenched by
spotting 15 μL onto P81 phosphocellulose paper (What-
man; GE Healthcare, Little Chalfont, UK), followed by
repeated washes in 1% (v/v) phosphoric acid. 32P transfer
was quantiﬁed by liquid scintillation counting (Perki-
nElmer, MA, USA).
GTPase activity assay
Recombinant human Drp1 was incubated with Mdivi-1
at 37 °C for 30 min and GTPase activity of Drp1 was
determined using the GTPase assay kit (Novus Biologi-
cals, CO, USA) according to the manufacturer’s
instructions.
Analysis of mitochondrial respiration and glycolysis
All extracellular ﬂux analyses were performed using the
Seahorse XFe96 Extracellular Flux Analyser (Agilent,
Santa Clara, USA). Brieﬂy, iPSCs were plated at 5 × 104
cells/well in a 96-well Seahorse V3-PS plate pre-coated
with growth factor reduced Matrigel (1:60 dilution). After
overnight incubation and prior to assay, cells were washed
with assay media (Seahorse XF base medium supple-
mented with 25 mM glucose, 1 mM glutamine and 1mM
sodium pyruvate for OCR assay, or Seahorse XF base
medium supplemented with 1 mM glutamine for ECAR
assay), and equilibrated in 175 μL of respective assay
media per well at 37 °C with no CO2 for 30min. The assay
protocol consisted of repeated cycles of 3 min mix and 3
min measurement periods, with OCR and ECAR mea-
sured simultaneously. Basal energetics were established
after four of these initial cycles, followed by performing a
mitochondrial stress test which includes sequential
injection of the following compounds and subsequent
measurement of OCR after each: the ATP synthase inhi-
bitor oligomycin (1 μM), the proton ionophore carbonyl
cyanide-4-(triﬂuoromethoxy)phenylhydrazone (FCCP,
125 nM) together with sodium pyruvate (1 mM), and the
mitochondrial complex III and Complex I inhibitors
antimycin A/rotenone (1 µM). The glycolysis stress test
includes sequential injection of the following compounds
and subsequent measurement of ECAR after each: glucose
(10 mM), oligomycin (1 μM), and 2-deoxy-glucose (2DG,
50mM). All treatment conditions were analysed as 2–4
replicates for each independent experiment. At the com-
pletion of each assay, cells were lysed and protein con-
centration was determined using the Bradford dye-
binding method (Bio-Rad, Sydney, Australia) according
to the manufacturer’s instructions.
Statistics
All values are expressed as mean ± standard error of the
mean (SEM). Signiﬁcance of the differences was evaluated
using unpaired Student’s t-test or one-way ANOVA fol-
lowed by Bonferroni multiple comparison post hoc ana-
lyses where appropriate. P < 0.05 was considered
statistically signiﬁcant.
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